ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab

Am J Transplant. 2005 Jan;5(1):145-8. doi: 10.1111/j.1600-6143.2004.00653.x.

Abstract

ABO incompatible kidney transplantations have previously only been performed after several preoperative sessions of plasmapheresis and splenectomy, with the conventional triple-drug immunosuppressive protocol being reinforced with antilymphocyte globulin and B-cell-specific drugs, such as cyclophosphamide or deoxyspergualine. We have designed a protocol without splenectomy, based on antigen-specific immunoadsorption, rituximab and a conventional triple-drug immunosuppressive protocol. The protocol calls for a 10-day pretransplantation conditioning period, starting with one dosage of rituximab and followed by full dose tacrolimus, mycophenolate mofetil and prednisolone. Antigen-specific immunoadsorption was performed on pretransplantation days -6, -5, -2 and -1. After the last session, 0.5 g/kg of intravenous immunoglobulin (IVIG) was administered. Postoperatively, three more apheresis sessions were given every third day. Furthermore, if there was a significant increase in the antibody titers, extra sessions were considered. Eleven patients have received transplants with this protocol. The ABO antibodies were readily removed by the antigen-specific immunoadsorption and were kept at a low level post-transplantation by further adsorptions. There were no side effects and all patients have normal renal transplant function. We conclude that after an infusion each of rituximab and IVIG, and antigen-specific immunoadsorption; blood group-incompatible renal transplantations can be performed with excellent results using standard immunosuppression and no splenectomy.

Publication types

  • Clinical Trial

MeSH terms

  • ABO Blood-Group System
  • Adsorption
  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens / chemistry
  • Antigens, CD20 / biosynthesis
  • Antineoplastic Agents / pharmacology
  • B-Lymphocytes / immunology
  • B-Lymphocytes / metabolism
  • Blood Component Removal
  • Blood Group Incompatibility*
  • Creatinine / blood
  • Female
  • Humans
  • Immunoglobulins, Intravenous / pharmacology
  • Immunosorbent Techniques*
  • Immunosuppressive Agents / pharmacology
  • Kidney Transplantation / methods*
  • Male
  • Middle Aged
  • Mycophenolic Acid / administration & dosage
  • Mycophenolic Acid / analogs & derivatives*
  • Prednisolone / administration & dosage
  • Rituximab
  • Splenectomy
  • Tacrolimus / administration & dosage
  • Time Factors
  • Transplantation Conditioning

Substances

  • ABO Blood-Group System
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens
  • Antigens, CD20
  • Antineoplastic Agents
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Rituximab
  • Prednisolone
  • Creatinine
  • Mycophenolic Acid
  • Tacrolimus